Review top news and interview highlights from the week ending September 2, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.
The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.
The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.
The in vivo genome-editing therapy is the first gene therapy to be evaluated in a clinical trial for preventing HAE attacks.
The risk-benefit assessment determined that there are no significant safety concerns.
Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy
June 18th 2025In honor of Alzheimer's & Brain Awareness Month, observed annually in June, we took a look back at recent news and insights in cell and gene therapy for Alzheimer disease and other dementias.
Eugenio Galli, MD, PhD, on Reexamining Frailty as a Barrier to CAR-T Treatment
June 16th 2025The hematologist at the Hematology and Stem Cell Transplants Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome discussed a study on the effect of comorbidities in patients receiving CAR-T.